elezanumab

Home
Ligands
elezanumab

GtoPdb Ligand ID: 9290

Synonyms: ABT-555 | AE12-1Y-QL

Comment: Elezanumab (ABT-555) is a fully human monoclonal antibody targeting repulsive guidance molecule-a (RGMA), in development as a potential therapy for multiple sclerosis (MS).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2013112922 [2].

References
1. Demicheva E, Cui YF, Bardwell P, Barghorn S, Kron M, Meyer AH, Schmidt M, Gerlach B, Leddy M, Barlow E et al.. (2015) Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis. Cell Rep, 10 (11): 1887-98. [PMID:25801027]
2. Mueller B, Huang L, Bardwell PD, Kutsova Y, Memmot J. (2013) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration. Patent number: WO2013112922 A1. Assignee: AbbVie Deutschland GmbH & Co. KG, Abbvie Inc.. Priority date: 27/01/2012. Publication date: 01/08/2013.

References

1. Demicheva E, Cui YF, Bardwell P, Barghorn S, Kron M, Meyer AH, Schmidt M, Gerlach B, Leddy M, Barlow E et al.. (2015)
Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis.
Cell Rep, 10 (11): 1887-98. [PMID:25801027]

2. Mueller B, Huang L, Bardwell PD, Kutsova Y, Memmot J. (2013)
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration.
Patent number: WO2013112922 A1. Assignee: AbbVie Deutschland GmbH & Co. KG, Abbvie Inc.. Priority date: 27/01/2012. Publication date: 01/08/2013.